PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Fenpiverinium→

Fenpiverinium PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
258329-46-3
Molecular formula
C22H29N2O+
Molecular weight
337.5 g/mol
Drug class
Quaternary ammonium antimuscarinicantispasmodic component of fixed-dose analgesic combinations
Mechanism of action
Antagonises muscarinic acetylcholine receptors in visceral smooth muscle, reducing cholinergic tone and intestinal, biliary and urinary tract spasm. It is commonly used in combination with metamizole and pitofenone rather than as a stand-alone product.
Indications / reported uses
  • Component of fixed-dose combinations used for short-term symptomatic relief of painful gastrointestinal, biliary or urinary smooth-muscle spasm, where authorised.

Sources: https://pubmed.ncbi.nlm.nih.gov/6719639/ · https://www.rlsnet.ru/active-substance/metamizol-natriya-pitofenon-fenpiveriniya-bromid-246 · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Fenpiverinium PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fenpiverinium Permitted Daily Exposure (PDE) report (the Fenpiverinium PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fenpiverinium Occupational Exposure Limit (OEL) report (the Fenpiverinium OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.